Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Sam D. Molyneux, … , Lawrence S. Kirschner, Rama Khokha
Published August 9, 2010
Citation Information: J Clin Invest. 2010;120(9):3310-3325. https://doi.org/10.1172/JCI42391.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 15

Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice

  • Text
  • PDF
Abstract

Some cancers have been stratified into subclasses based on their unique involvement of specific signaling pathways. The mapping of human cancer genomes is revealing a vast number of somatic alterations; however, the identification of clinically relevant molecular tumor subclasses and their respective driver genes presents challenges. This information is key to developing more targeted and personalized cancer therapies. Here, we generate a new mouse model of genomically unstable osteosarcoma (OSA) that phenocopies the human disease. Integrative oncogenomics pinpointed cAMP-dependent protein kinase type I, α regulatory subunit (Prkar1a) gene deletions at 11qE1 as a recurrent genetic trait for a molecularly distinct subclass of mouse OSA featuring RANKL overexpression. Using mouse genetics, we established that Prkar1a is a bone tumor suppressor gene capable of directing subclass development and driving RANKL overexpression during OSA tumorigenesis. Finally, we uncovered evidence for a PRKAR1A-low subset of human OSA with distinct clinical behavior. Thus, tumor subclasses develop in mice and can potentially provide information toward the molecular stratification of human cancers.

Authors

Sam D. Molyneux, Marco A. Di Grappa, Alexander G. Beristain, Trevor D. McKee, Daniel H. Wai, Jana Paderova, Meenakshi Kashyap, Pingzhao Hu, Tamara Maiuri, Swami R. Narala, Vuk Stambolic, Jeremy Squire, Josef Penninger, Otto Sanchez, Timothy J. Triche, Geoffrey A. Wood, Lawrence S. Kirschner, Rama Khokha

×

Figure 2

Characterization of OSA in MOTO mice.

Options: View larger image (or click on image) Download as PowerPoint
Characterization of OSA in MOTO mice.
Gross images of tumors in (A) femu...
Gross images of tumors in (A) femur, (B) spine, (C) skull (arrows), and (D) ribs. (E–I) Paraffin sections of osteoblastic tumors: (E) Aggressive skull tumor with cortical destruction (stained with H&E), (F) humerus with parosteal tumors (arrows) with lesions that are continuous with cortex (open arrow) or within the medulla (open arrowhead) (stained with H&E), (G) tumor with cellular atypia (stained with H&E), and (H) Masson’s trichrome–stained collagen-rich osteoid. (I) Alkaline phosphatase staining shows osteoblast specificity. Spontaneous OSA metastases: (J, K, and M) Lung metastases are approximately 1–2 mm, disc shaped, and superficial, (N, O, and Q) while liver metastases are up to 8 mm, spherical, and (O) embedded deeper in the parenchyma (stained with H&E). (K) Masson’s trichrome–stained collagen shows the osteoblastic nature of metastases. (M and Q) The prominent disorganized collagen in the metastases can be visualized by the second harmonic signal that it generates (green). The red signal is autofluorescence of cellular proteins. (L) WT lung and (P) liver are shown for comparison. Scale bars: 1 mm (E, F, and O); 150 μm (K); 50 μm (G–I, K, inset, L, M, P, and Q).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Referenced in 3 patents
On 1 Facebook pages
56 readers on Mendeley
1 readers on CiteULike
See more details